Companies featured in our PharmaVoice 100 list have been making waves in the industry. 

Prothena, whose CEO Gene Kinney landed in the list’s “Standout Leaders” category, announced promising midstage results this week for a Roche-partnered Parkinson’s drug. Although the treatment, prasinezumab, missed the trial’s primary endpoint in motor progression, the companies said it showed “potential clinical effect,” particularly in patients also treated with the longtime Parkinson’s gold standard levodopa, as well as “positive trends” on other endpoints. Despite the mixed results, the news sent Prothena’s stock soaring yesterday over 30%, a testament to the magnitude of the subgroup achievement. 

Like every year, the PharmaVoice 100, which showcases the executives, companies and trends shaping the industry, was one of our most popular features in 2024. Today, we’re looking back at the articles you clicked on most this year — some reflecting pharma’s most critical issues while others were just plain fun to read. We’re also looking at the FDA’s highly anticipated decision on GLP-1 shortages and how it could affect compounded versions of the bestselling drugs. 

Editor’s note: Nominations for next year’s PharmaVoice 100 are also open. Send us the name of the colleague or friend you think would be a good fit for the list in 2025. 

Thanks for reading, and have a happy holiday season!